Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aerie Pharmaceuticals (NQ: AERI )

18.39 USD +2.58 (+16.32%)
Official Closing Price Updated: 5:51 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,646,400
Open 16.23
Bid (Size) 17.48 (3)
Ask (Size) 18.45 (1)
Prev. Close 15.81
Today's Range 15.76 - 18.87
52wk Range 9.010 - 19.42
Shares Outstanding 39,496,520
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients... 
From Business Wire News Releases
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients... 
From Business Wire News Releases

Performance

YTD
+40.17%
+40.17%
1 Month
+6.98%
+6.98%
3 Month
+48.19%
+48.19%
6 Month
+67.18%
+67.18%
1 Year
+2.85%
+2.85%

More News

Read More
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
From Business Wire News Releases
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
From Business Wire News Releases
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union
From Business Wire News Releases
Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
From Business Wire News Releases
Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
From Business Wire News Releases
The Math Shows IHE Can Go To $215
Tags ETFs
From ETF Channel
Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
From Business Wire News Releases
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
From Business Wire News Releases
Analysts Predict 15% Upside For The Holdings of IHE
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.